References
- George JN, Woolf SH, Raskob GE et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood88(1), 3–40 (1996).
- Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch. Intern. Med.160(11), 1630–1638 (2000).
- Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood97(9), 2549–2554 (2001).
- Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin. Proc.79(4), 504–522 (2004).
- Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood106(7), 2244–2251 (2005).
- George JN. Management of patients with refractory immune thrombocytopenic purpura. J. Thromb. Haemost.4(8), 1664–1672 (2006).
- Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin. Hematol.43(3 Suppl. 5), S3–S10 (2006).
- Stasi R, Stipa E, Masi M et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am. J. Med.98(5), 436–442 (1995).
- Cheng Y, Wong RS, Soo YO et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N. Engl. J. Med.349(9), 831–836 (2003).
- Mazzucconi MG, Fazi P, Bernasconi S et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood109(4), 1401–1407 (2007).
- Scaradavou A, Woo B, Woloski BM et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood89(8), 2689–2700 (1997).
- Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood104(9), 2623–2634 (2004).
- Arnold DM, Dentali F, Crowther MA et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann. Intern. Med.146(1), 25–33 (2007).
- Gernsheimer T. Epidemiology and pathophysiology of immune thrombocytopenic purpura. Eur. J. Haematol. Suppl. (69), 3–8 (2008).
- Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br. J. Haematol.122(6), 966–974 (2003).
- Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J. Thromb. Haemost.4(11), 2377–2383 (2006).
- Ruggeri M, Fortuna S, Rodeghiero F. Heterogeneity of terminology and clinical definitions in adult idiopathic thrombocytopenic purpura: a critical appraisal from a systematic review of the literature. Haematologica93(1), 98–103 (2008).
- Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb. Haemost.99(1), 4–13 (2008).
- Kuter DJ, Bussel JB, Lyons RM et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet371(9610), 395–403 (2008).
- Kaushansky K. Thrombopoietin: accumulating evidence for an important biological effect on the hematopoietic stem cell. Ann. NY Acad. Sci.996, 39–43 (2003).
- Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev.13(1), 61–73 (2002).
- Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood89(1), 101–107 (1997).
- Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood86(2), 419–431 (1995).
- Fielder PJ, Gurney AL, Stefanich E et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood87(6), 2154–2161 (1996).
- Li J, Xia Y, Kuter DJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br. J. Haematol.106(2), 345–356 (1999).
- Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene21(21), 3359–3367 (2002).
- Siegel RS, Rae JL, Barth S et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am. J. Hematol.30(4), 206–212 (1989).
- Louwes H, Zeinali Lathori OA, Vellenga E, de Wolf JT. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am. J. Med.106(4), 430–434 (1999).
- Hoffman R, Zaknoen S, Yang HH et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N. Engl. J. Med.312(18), 1170–1174 (1985).
- Chang M, Nakagawa PA, Williams SA et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood102(3), 887–895 (2003).
- Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood93(6), 1951–1958 (1999).
- Chang M, Qian JX, Lee SM et al. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice. Blood93(8), 2515–2524 (1999).
- Kosugi S, Kurata Y, Tomiyama Y et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br. J. Haematol.93(3), 704–706 (1996).
- Porcelijn L, Folman CC, Bossers B et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb. Haemost.79(6), 1101–1105 (1998).
- Kuter DJ. New thrombopoietic growth factors. Blood109(11), 4607–4616 (2007).
- Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood98(12), 3241–3248 (2001).
- Kaushansky K. Hematopoietic growth factor mimetics. Ann. NY Acad. Sci.938, 131–138 (2001).
- Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Curr. Drug Discov. Technol.4(3), 162–173 (2007).
- Erickson-Miller CL, DeLorme E, Tian SS et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol.33(1), 85–93 (2005).
- Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs68(7), 901–912 (2008).
- Erickson-Miller CL, DeLorme E, Iskander M et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood104 (2004) (Abstract 2909).
- Jenkins JM, Williams D, Deng Y et al. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood109(11), 4739–4741 (2007).
- Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood104 (2004) (Abstract 3888).
- Bussel JB, Cheng G, Saleh MN et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N. Engl. J. Med.357(22), 2237–2247 (2007).
- Bussel J, Provan A, Shamsi T et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a Phase III study. Haematologica92(Suppl. 1) (2007) (Abstract 0390).
- Bussel JB, Cheng G, Saleh M et al. Long-term safety and efficacy of oral eltrombopag for the treatment of idiopathic thrombocytopenic purpura (ITP). Haematologica93(Suppl. 1) (2008) (Abstract 0949).
- Psaila B, Bussel JB, Vasey S et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic ITP. Haematologica93(Suppl. 1) (2008) (Abstract 0294).
- Ulich TR, del Castillo J, Senaldi G et al. Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice. Blood87(12), 5006–5015 (1996).
- Villeval JL, Cohen-Solal K, Tulliez M et al. High thrombopoietin production by hematopoietic cells induces a fatal myeloproliferative syndrome in mice. Blood90(11), 4369–4383 (1997).
- Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br. J. Haematol.139(3), 351–362 (2007).
- Bussel JB, Schindler AM, Grossbard EB. R935788: a Phase II, single center, open label, efficacy and safety, ascending dose, pilot study for the treatment of adult immune thrombocytopenic purpura (ITP). Blood110(11) (2007) (Abstract 1310).
Website
- RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura Study With Eltrombopag www.clinicaltrials.gov/ct2/results?term=NCT00370331